Alzinova AB (publ) (“Alzinova” or the “Company”) presents data for the Company's preclinical antibody candidate ALZ-201 at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, to be held in San Francisco from 29 November to 2 December. Alzinova’s Chief Scientific Officer Anders Sandberg will summarise the antibody's unique binding profile in a poster presentation titled "ALZ-201, a monoclonal antibody therapy for specific neutralization of toxic amyloid-β in Alzheimer's disease".
Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease, focuses specifically on the toxic forms of amyloid-beta, the oligomers, which have attracted increasing interest. Preclinical data show that the Company's drug candidates in development have "best-in-class" potential, and clinical results from other players in the field reinforce the Company's strategy. The Company has participated in several partnering and investor meetings this fall and will now present a poster at CTAD.
The poster summarises the development of the monoclonal antibody ALZ-201 and its unique binding profile in relation to other drug candidates in development. The data show that ALZ-201 differs significantly from lecanemab, aducanumab, and gantenerumab in that, unlike these, binds specifically to a small portion of the amyloid beta known as oligomers. With this targeted binding profile, ALZ-201 has a strong neutralising effect on the toxic form of amyloid beta extracted from the brains of deceased Alzheimer's patients. Specificity for the amyloid beta that is toxic, is thought to be necessary to obtain a good therapeutic effect in patients with Alzheimer's disease.
CTAD is a highly regarded annual Alzheimer's conference that will be held this year from 29 November to 2 December 2022 in San Francisco. The conference, which is focused on clinical development of new drug candidates for the treatment of Alzheimer's disease, attracts many prominent leaders in research, industry, and academia.
ALZINOVA AB 
